ESMO 2023


Session Info Card

Session Info Card

Tisotumab Vedotin | Cervical Cancer | Abstract #LBA9

innovaTV 301/ENGOT-cx12/GOG-3057: a randomized, open-label, phase 3 study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer

Enfortumab Vedotin | Urothelial Cancer | Abstract #LBA6

EV-302/KEYNOTE-A39: Open-label, randomized phase 3 study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)

Enfortumab Vedotin | Bladder Cancer | Abstract #813

Study EV-103 Cohort L: perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC)

Tucatinib | Colorectal Cancer | Abstract #857

Impact of baseline molecular alterations on the efficacy of tucatinib (TUC) plus trastuzumab (Tras) for HER2+, RAS WT metastatic CRC (mCRC) in MOUNTAINEER

Tucatinib | Gastroesophageal Cancer | Abstract #1914

Phase 2 dose optimization results from MOUNTAINEER-02: a study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC)

SGN-B7H4V | Solid Tumors | Abstract #1546

First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: preliminary results of a phase 1 study (SGNB7H4V-001)